Insider News
Sep 9, 2024
Sep 23, 2024
BioProcess Insider Daily - Biotech Week Boston
Read More
Cell therapies will play an increasingly important position in AstraZeneca’s broad oncology pipeline, an SVP told delegates at Biotech Week Boston (BWB) last month.
Smaller innovators are more likely to be upended by US legislation aimed at restricting working with China-based CDMOs like WuXi Biologics, according to Latham Biopharm.
Vertex says finding the sweet spot in manufacturing capacity is key to ensuring the successful rollout of sickle cell gene therapy Casgevy (exagamglogene autotemcel).
A President Biden Executive Order supporting homegrown biomanufacturing will remain in place whoever wins in November, White House OSTP assistant director Sarah Glaven told Biotech Week Boston delegates.
Latest Issue
Current Issue
From Pipettes to Infusion Pumps: Volume Accuracy in Regulated Industries and Its Critical Impact
Latest eBooks
See All
Special Reports
As the monoclonal-antibody (mAb) market continues to grow, it is becoming increasingly important for pharmaceutical and biotech companies to accelerate process development and establish a scalable manufacturing process capable of achieving high titers and consistent product quality. Central to this is a cell culture media and feed system that can provide the required nutrients for optimal cell growth, viability, and function, as well as facilitate a seamless transition from development to clinical and commercial manufacturing. However, choosing an appropriate system can be a complex and time-consuming process, often requiring the evaluation of multiple medium and feed options. Platform systems, consisting of a medium and complementary feed developed for a specific cell line and application, have emerged as a valuable option for developers to help simplify selection and increase scale-up efficiency. To meet the need for high-performance platform mAb manufacturing solutions, Thermo Fisher Scientific has dev...
Precision in volume delivery is critically important for both the biopharmaceutical and medical device industries. This special report discusses how accurate volume measurement affects patient safety, product quality, and regulatory compliance. Sartorius emphasizes the roles that infusion pumps, laboratory pipettes, and quality control (QC) measures play in ensuring reliable and reproducible results. Register or Login and hit Download Now to get the full Special Report.
Ask the Expert Webcasts
Poloxamer 188 is a surfactant with a longstanding history of use in pharmaceutical drugs, spanning dosage routes from oral to topical and parenteral administration. In the biomanufacturing space, it finds application not only as a surfactant for parenteral biological formulations, but also in cell culture as a shear stress protectant. Its specific surfactant properties make it effective at stabilizing proteins, as well as protecting cells from shear stress caused by agitation in a bioreactor. Poloxamer 188 has the ability to prevent cell shear stress due to its specific balance of hydrophobic PPO chain flanked by two blocks of hydrophilic PEO. However, impurities from the manufacturing process can compromise its performance, leading to detrimental effects on cell health and contributing to batch-batch inconsistency. One persistent challenge in the market has been the search for reliable manufacturers of poloxamer 188 with the ability to produce consistent materials exhibiting consistent batch-to-batch per...
This webcast features: David Seifert, head of sales application engineering sterile consumables & Khalil Essani , product line manager, sterile consumables, Single Use Support. The pandemic should have taught us that dual or multi-sourcing helps to strengthen supply chains. But did you know that the implications for manufacturers and CDMOs are even greater? Join this webinar to learn more about the possibilities of using vendor-independent components for your biopharmaceutical fluid path. Key Takeaways: Register or Login and hit Watch on Demand to view the recorded webcast now.
